An application made for this job — a tailored resume and cover letter that speak straight to the posting.
MoonLake Immunotherapeutics is seeking a Director of Business Intelligence to partner with the Commercial organization, translating market, patient, payer, and competitive insights into actionable actions that accelerate launch readiness and optimize commercial performance.
The role leads the BI function for a major dermatology product launch, integrating primary market research, secondary analytics, and healthcare data to inform brand strategy, market access, and deployment decisions.
The Director, Business Intelligence will serve as a strategic partner to the Commercial organisation, ensuring that market, customer, patient, payer and competitive insights are translated into actionable business decisions that accelerate launch readiness and optimise commercial performance.
As MoonLake prepares for a major product launch in Dermatology, this individual will lead the business intelligence function, generating insights that inform brand strategy, go-to-market planning, market access, customer engagement, investment prioritisation and launch execution.
This role requires a proven launch professional with demonstrated experience supporting the successful pre-launch, launch and post-launch phases of a specialty pharmaceutical or biotechnology brand. The individual will integrate primary market research, secondary analytics, healthcare claims data, competitive intelligence to identify opportunities, anticipate risks and influence key commercial decisions.
Working closely with Marketing, Commercial Analytics, Market Access, the individual will ensure the organisation maintains a deep understanding of customers, market dynamics, marketing analytics and competitive developments throughout the launch journey.
MoonLake is a dynamic and innovative company pushing the boundaries of possibility, and we are looking for passionate individuals to join our stellar team.
MoonLake Immunotherapeuticsis a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody for the treatment of the inflammatory disease, to revolutionize outcomes for patients.
We continue to make significant progress in our Global Clinical Development Programs. The company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis - conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquarted in Zug, with hubs in Cambridge & Porto.
Further information is available at www.moonlaketx.com